M
Markus Magerl
Researcher at Charité
Publications - 160
Citations - 7386
Markus Magerl is an academic researcher from Charité. The author has contributed to research in topics: Hereditary angioedema & Angioedema. The author has an hindex of 41, co-authored 146 publications receiving 5758 citations. Previous affiliations of Markus Magerl include University of Bradford.
Papers
More filters
Journal ArticleDOI
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,A H Abdul Latiff,Diane Baker,Barbara Ballmer-Weber,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Zenon Brzoza,R Buense Bedrikow,G.W. Canonica,Martin K. Church,Timothy J. Craig,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,C. Katelaris,Emek Kocatürk,Kanokvalai Kulthanan,D. Larenas-Linnemann,Tabi A. Leslie,Markus Magerl,P. Mathelier-Fusade,R. Y. Meshkova,Martin Metz,Alexander Nast,Eustachio Nettis,Hanneke Oude-Elberink,Stefanie Rosumeck,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Christian Vestergaard,Bettina Wedi,Ricardo Niklas Werner,Zuotao Zhao,Marcus Maurer +48 more
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Journal ArticleDOI
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update
Marcus Maurer,Markus Magerl,I. J. Ansotegui,Emel Aygören-Pürsün,Stephen Betschel,Konrad Bork,Tom Bowen,H. Balle Boysen,Henriette Farkas,Anete Sevciovic Grumach,Michihiro Hide,Constance H. Katelaris,R. Lockey,Hilary Longhurst,W. R. Lumry,Inmaculada Martinez-Saguer,Dumitru Moldovan,Alexander Nast,Ruby Pawankar,Paul Potter,Marc A. Riedl,Bruce Ritchie,Lanny J. Rosenwasser,Mario Sánchez-Borges,Yuxiang Zhi,Bruce L. Zuraw,Timothy J. Craig +26 more
TL;DR: The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of H AE with deficient C1‐inhibitor (type 1) and HAE with dysfunctional C1-inhibitors (type 2).
Journal ArticleDOI
The definition, diagnostic testing, and management of chronic inducible urticarias – The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision
Markus Magerl,Sabine Altrichter,Elena Borzova,A. Giménez-Arnau,Clive Grattan,F. Lawlor,P. Mathelier-Fusade,R. Y. Meshkova,T. Zuberbier,Martin Metz,Marcus Maurer +10 more
TL;DR: These recommendations for the definition, diagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update the previous consensus report on physical urticarias and cholinergic uricaria (Allergy, 2009), and acknowledge the latest changes in understanding of CIndU.
Journal ArticleDOI
WAO Guideline for the Management of Hereditary Angioedema
Timothy J. Craig,Emel A.ygören Pürsün,Konrad Bork,Tom Bowen,Henrik Balle Boysen,Henriette Farkas,Anete Sevciovic Grumach,Constance H. Katelaris,Richard F. Lockey,Hilary Longhurst,William R. Lumry,Markus Magerl,Immaculada Martinez-Saguer,Bruce Ritchie,Alexander Nast,Ruby Pawankar,Bruce L. Zuraw,Marcus Maurer +17 more
TL;DR: In this article, a group of specialists focused on hereditary angioedema (HAE) from around the world have developed a con- sensus on diagnosis and management of HAE, but also provide evidence based grades, strength of evidence and classification for the consensus.
Journal ArticleDOI
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity
Petra Staubach,Annegret Eckhardt-Henn,M. Dechene,A. Vonend,Martin Metz,Markus Magerl,Peter Breuer,Marcus Maurer +7 more
TL;DR: This study focuses on the treatment of chronic urticaria with a single agent, which has the potential to dramatically improve the quality of life of patients with this disorder.